We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MD Gains 11% Since Q4 Earnings Release, Unveils '25 View
Read MoreHide Full Article
Pediatrix Medical Group, Inc. (MD - Free Report) shares rose 10.6% since it reported fourth-quarter 2024 results on Feb. 20, 2025. The quarterly results benefited on the back of strong same-unit revenue growth, improved payor mix and higher hospital contract administrative fees. A decline in the overall expense level also contributed to the upside. However, the upside was partly offset by higher same-unit clinical compensation costs.
See the Zacks Earnings Calendar to stay ahead of market-making news.
MD reported fourth-quarter 2024 adjusted earnings per share (EPS) of 51 cents, which surpassed the Zacks Consensus Estimate by 37.8%. The bottom line soared 59.4% year over year.
Net revenues were $502.4 million, which inched up 1.2% year over year. The top line beat the consensus mark by 3.4%.
Pediatrix Medical Group, Inc. Price, Consensus and EPS Surprise
Same-unit revenues improved 8.7% year over year, beating the Zacks Consensus Estimate and our estimate of 4.3%. Same-unit revenues, attributable to patient volume, grew 2.8% year over year.
Same-unit revenues from net reimbursement-related factors advanced 5.9% year over year on the back of decent growth in hospital contract administrative fees and improved payor mix. It beat the Zacks Consensus Estimate and our estimate of 2.7%.
Pediatrix Medical’s total operating expenses declined 23.8% year over year to $463.1 million, higher than our estimate of $447.9 million. The decrease was attributable to lower practice salaries and benefits, and practice supplies and other operating expenses.
Practice salaries and benefits fell 4% on a year-over-year basis on the back of the impact of practice dispositions. Interest expenses of $9.7 million slid 3.7% year over year but were higher than our estimate of $9.6 million.
MD’s net income totaled $30.5 million against the prior-year quarter’s loss of $124.3 million.
Adjusted EBITDA climbed 35.2% year over year to $68.7 million, which beat our estimate of $53.8 million.
MD’s Financial Update (as of Dec. 31, 2024)
Pediatrix Medical exited the fourth quarter with cash and cash equivalents of $229.9 million, which increased more than three-fold from the 2023-end figure. There were no outstanding borrowings on its revolving credit facility at the quarter-end.
Total assets of $2.2 billion tumbled 3% from the level at 2023-end.
Total debt, including finance leases, net, amounted to $617.7 million, down 2.5% from the figure as of Dec. 31, 2023.
Total shareholders’ equity of $764.9 million decreased 9.9% from the 2023-end figure.
Operating cash flow surged 50.4% from the 2023-end level to $206.6 million in 2024.
Share Repurchase Update for MD
Pediatrix Medical bought back common shares for $1.7 million in 2024. It had a leftover capacity of $2.9 million under its $500 million repurchase program (approved in August 2018) as of Dec. 31, 2024.
MD’s 2025 View Unveiled
Management projects adjusted EBITDA to be between $215 million and $235 million, the midpoint of which indicates a 0.4% increase from the 2024 reported figure of $224.1 million. Net income is estimated to be between $98.3 million and $112.9 million. A loss of $99.1 million was incurred in 2024.
Interest expense is forecasted at $37.9 million for 2025, which implies a 7.1% decline from the 2024 figure of $40.7 million. Income tax expense is expected to be in the range of $36.4-$41.8 million.
Depreciation and amortization expenses are estimated to be $27.5 million. Transformational and restructuring-related expenses are expected at $14.9 million.
Of the Medical sector players that have reported fourth-quarter 2024 results so far, the bottom-line results of Centene Corporation (CNC - Free Report) , Tenet Healthcare Corporation (THC - Free Report) and Encompass Health Corporation (EHC - Free Report) beat the respective Zacks Consensus Estimate.
Centene reported fourth-quarter 2024 adjusted EPS of 80 cents, which outpaced the Zacks Consensus Estimate by 63.3%. Moreover, the bottom line rose 77.8% year over year. Revenues were $40.8 billion, which increased 3.4% year over year. The top line surpassed the consensus mark by 4.8%. Revenues from Medicaid dipped 1% year over year to $20.8 billion, while Medicare revenues grew 4% year over year to $5.5 billion. Additionally, commercial revenues of $8.7 billion climbed 18% year over year.
Centene's premiums amounted to $35.5 billion, rising 3.8% year over year. Service revenues decreased 29.7% year over year to $777 million. Investment and other income of $344 million dipped 14.2% year over year. As of Dec. 31, 2024, total membership was 28.6 million, which grew 4.1% year over year. Centene’s HBR deteriorated 10 basis points year over year to 89.6%. Adjusted net earnings of $404 million rose 68.3% year over year.
Tenet Healthcare’s fourth-quarter 2024 adjusted EPS of $3.44 surpassed the Zacks Consensus Estimate by 17.4%. The bottom line increased 28.4% year over year. Net operating revenues declined 5.7% year over year to $5.1 billion. The top line missed the consensus mark by 1.8%. Adjusted net income was $330 million, which increased 16.6% year over year. Adjusted EBITDA increased 3.6% year over year to $1.05 billion. Adjusted EBITDA margin of 20.7% improved 190 basis points year over year.
The Hospital Operations and Services segment recorded net operating revenues of $3.81 billion, which fell 11.4% year over year. On a same-hospital basis, net patient service revenues improved 0.6% year over year. Adjusted EBITDA declined 5.5% year over year to $518 million. The Ambulatory Care unit’s net operating revenues climbed 16.9% year over year to $1.3 billion. Adjusted EBITDA of $530 million rose 14.2% year over year.
Encompass Health reported fourth-quarter adjusted EPS of $1.17, which beat the Zacks Consensus Estimate by 14.7%. The bottom line increased 23.2% year over year. Net operating revenues of $1.4 billion improved 12.8% year over year. The top line beat the consensus mark by 2.1%. EHC’s net patient revenue per discharge rose 4.2% year over year. Total discharges grew 7.8% year over year to 63,839.
Net and comprehensive income climbed 37.9% year over year to $164.2 million in the fourth quarter. Adjusted EBITDA of $289.6 million grew 13.6% year over year and surpassed our estimate of $261 million. In the fourth quarter, Encompass Health added 22 beds to its existing hospitals and inaugurated one de novo hospital. The unit’s operating gain of $0.6 billion remained stable year over year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
MD Gains 11% Since Q4 Earnings Release, Unveils '25 View
Pediatrix Medical Group, Inc. (MD - Free Report) shares rose 10.6% since it reported fourth-quarter 2024 results on Feb. 20, 2025. The quarterly results benefited on the back of strong same-unit revenue growth, improved payor mix and higher hospital contract administrative fees. A decline in the overall expense level also contributed to the upside. However, the upside was partly offset by higher same-unit clinical compensation costs.
See the Zacks Earnings Calendar to stay ahead of market-making news.
MD reported fourth-quarter 2024 adjusted earnings per share (EPS) of 51 cents, which surpassed the Zacks Consensus Estimate by 37.8%. The bottom line soared 59.4% year over year.
Net revenues were $502.4 million, which inched up 1.2% year over year. The top line beat the consensus mark by 3.4%.
Pediatrix Medical Group, Inc. Price, Consensus and EPS Surprise
Pediatrix Medical Group, Inc. price-consensus-eps-surprise-chart | Pediatrix Medical Group, Inc. Quote
Q4 Update for MD
Same-unit revenues improved 8.7% year over year, beating the Zacks Consensus Estimate and our estimate of 4.3%. Same-unit revenues, attributable to patient volume, grew 2.8% year over year.
Same-unit revenues from net reimbursement-related factors advanced 5.9% year over year on the back of decent growth in hospital contract administrative fees and improved payor mix. It beat the Zacks Consensus Estimate and our estimate of 2.7%.
Pediatrix Medical’s total operating expenses declined 23.8% year over year to $463.1 million, higher than our estimate of $447.9 million. The decrease was attributable to lower practice salaries and benefits, and practice supplies and other operating expenses.
Practice salaries and benefits fell 4% on a year-over-year basis on the back of the impact of practice dispositions. Interest expenses of $9.7 million slid 3.7% year over year but were higher than our estimate of $9.6 million.
MD’s net income totaled $30.5 million against the prior-year quarter’s loss of $124.3 million.
Adjusted EBITDA climbed 35.2% year over year to $68.7 million, which beat our estimate of $53.8 million.
MD’s Financial Update (as of Dec. 31, 2024)
Pediatrix Medical exited the fourth quarter with cash and cash equivalents of $229.9 million, which increased more than three-fold from the 2023-end figure. There were no outstanding borrowings on its revolving credit facility at the quarter-end.
Total assets of $2.2 billion tumbled 3% from the level at 2023-end.
Total debt, including finance leases, net, amounted to $617.7 million, down 2.5% from the figure as of Dec. 31, 2023.
Total shareholders’ equity of $764.9 million decreased 9.9% from the 2023-end figure.
Operating cash flow surged 50.4% from the 2023-end level to $206.6 million in 2024.
Share Repurchase Update for MD
Pediatrix Medical bought back common shares for $1.7 million in 2024. It had a leftover capacity of $2.9 million under its $500 million repurchase program (approved in August 2018) as of Dec. 31, 2024.
MD’s 2025 View Unveiled
Management projects adjusted EBITDA to be between $215 million and $235 million, the midpoint of which indicates a 0.4% increase from the 2024 reported figure of $224.1 million. Net income is estimated to be between $98.3 million and $112.9 million. A loss of $99.1 million was incurred in 2024.
Interest expense is forecasted at $37.9 million for 2025, which implies a 7.1% decline from the 2024 figure of $40.7 million. Income tax expense is expected to be in the range of $36.4-$41.8 million.
Depreciation and amortization expenses are estimated to be $27.5 million. Transformational and restructuring-related expenses are expected at $14.9 million.
MD’s Zacks Rank
Pediatrix Medical currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Other Medical Sector Releases
Of the Medical sector players that have reported fourth-quarter 2024 results so far, the bottom-line results of Centene Corporation (CNC - Free Report) , Tenet Healthcare Corporation (THC - Free Report) and Encompass Health Corporation (EHC - Free Report) beat the respective Zacks Consensus Estimate.
Centene reported fourth-quarter 2024 adjusted EPS of 80 cents, which outpaced the Zacks Consensus Estimate by 63.3%. Moreover, the bottom line rose 77.8% year over year. Revenues were $40.8 billion, which increased 3.4% year over year. The top line surpassed the consensus mark by 4.8%. Revenues from Medicaid dipped 1% year over year to $20.8 billion, while Medicare revenues grew 4% year over year to $5.5 billion. Additionally, commercial revenues of $8.7 billion climbed 18% year over year.
Centene's premiums amounted to $35.5 billion, rising 3.8% year over year. Service revenues decreased 29.7% year over year to $777 million. Investment and other income of $344 million dipped 14.2% year over year. As of Dec. 31, 2024, total membership was 28.6 million, which grew 4.1% year over year. Centene’s HBR deteriorated 10 basis points year over year to 89.6%. Adjusted net earnings of $404 million rose 68.3% year over year.
Tenet Healthcare’s fourth-quarter 2024 adjusted EPS of $3.44 surpassed the Zacks Consensus Estimate by 17.4%. The bottom line increased 28.4% year over year. Net operating revenues declined 5.7% year over year to $5.1 billion. The top line missed the consensus mark by 1.8%. Adjusted net income was $330 million, which increased 16.6% year over year. Adjusted EBITDA increased 3.6% year over year to $1.05 billion. Adjusted EBITDA margin of 20.7% improved 190 basis points year over year.
The Hospital Operations and Services segment recorded net operating revenues of $3.81 billion, which fell 11.4% year over year. On a same-hospital basis, net patient service revenues improved 0.6% year over year. Adjusted EBITDA declined 5.5% year over year to $518 million. The Ambulatory Care unit’s net operating revenues climbed 16.9% year over year to $1.3 billion. Adjusted EBITDA of $530 million rose 14.2% year over year.
Encompass Health reported fourth-quarter adjusted EPS of $1.17, which beat the Zacks Consensus Estimate by 14.7%. The bottom line increased 23.2% year over year. Net operating revenues of $1.4 billion improved 12.8% year over year. The top line beat the consensus mark by 2.1%. EHC’s net patient revenue per discharge rose 4.2% year over year. Total discharges grew 7.8% year over year to 63,839.
Net and comprehensive income climbed 37.9% year over year to $164.2 million in the fourth quarter. Adjusted EBITDA of $289.6 million grew 13.6% year over year and surpassed our estimate of $261 million. In the fourth quarter, Encompass Health added 22 beds to its existing hospitals and inaugurated one de novo hospital. The unit’s operating gain of $0.6 billion remained stable year over year.